Low MA / low clot stiffness after massive bleeding
After massive bleeding, low clot strength may reflect platelet contribution, fibrinogen contribution, dilution, physiology, or a mixed deficit. The key is to separate the components before choosing treatment.
Clinical scenario
A 59-year-old woman undergoing major liver resection develops rapid blood loss after hepatic vein injury. After surgical control is partially achieved, bleeding remains diffuse. She has received crystalloid, red cells, plasma, and cell salvage. Temperature is 35.1°C, pH is 7.24, ionized calcium is low, platelet count is 68,000/µL, and fibrinogen is low. TEG shows low MA and reduced functional fibrinogen contribution.
The team asks whether this is mainly a platelet problem.
Reasoning goals
- Recognize that massive bleeding creates mixed coagulopathy.
- Interpret low MA / low clot stiffness as a clot strength signal, not a platelet count surrogate.
- Separate platelet contribution from fibrinogen contribution.
- Correct physiology that prevents products from working.
- Reassess after targeted replacement.
- Keep surgical source control in view.
A. Why massive bleeding changes the interpretation
- Dilution, consumption, hypothermia, acidosis, low calcium, and ongoing loss evolve quickly.
- One VET result is a snapshot.
- Surgical source control and coagulation correction must proceed together.
B. What does low MA / low clot stiffness suggest?
- Reduced clot strength.
- May reflect platelet contribution, fibrinogen contribution, or both.
- Should not be equated with platelet count alone.
C. What does low functional fibrinogen contribution add?
- Fibrin contribution is also inadequate.
- Platelet therapy alone may not restore clot strength if fibrinogen is limiting.
- Mixed fibrinogen + platelet deficits are common in massive bleeding.
Low clot strength is usually a mixed signal
After massive bleeding, low MA reflects clot strength — not a platelet count. Separate the platelet and fibrinogen contributions, and correct physiology, before deciding which targeted replacement the pattern actually supports.
D. Action frame
- Confirm surgical control is adequate or actively improving.
- Correct temperature, pH, calcium, and dilution.
- Use the VET pattern plus standard labs to separate fibrinogen and platelet contribution.
- Consider fibrinogen replacement, platelet therapy, or both according to pattern and local protocol.
- Reassess clot strength and clinical bleeding after treatment.
E. What not to miss
- Ongoing surgical bleeding can keep diluting the patient.
- Low calcium and acidosis can make product therapy less effective.
- Platelet count alone does not explain clot quality.
Take-home message
After massive bleeding, low clot strength is usually a mixed signal. Separate fibrinogen contribution, platelet contribution, physiology, and source control before deciding the next intervention.
Clinical content by Kozo Watanabe, MD View profile →
Continue learning
Post-CPB diffuse bleeding: fibrinogen first or platelets first?
After CPB, diffuse bleeding with low fibrin-based clot firmness and reduced global clot strength can reflect fibrinogen deficit, platelet contribution, or both. The decision is pattern-based and must be reassessed.
Prolonged clotting time after CPB: heparin effect or factor deficiency?
After CPB, prolonged clotting time can reflect residual heparin, factor deficiency, dilution, hypothermia, sampling timing, or protamine effect. The key is not simply whether to give more protamine.
Normalized ROTEM but bleeding persists: think surgical source
When viscoelastic results improve but bleeding continues, the next question is not always more product. Reassess the surgical field, source control, timing, and physiology.